Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)
Launched by AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA · Jun 14, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called PhotoNodes, is studying a new way to evaluate the quality of surgery for patients with gastric cancer, specifically those undergoing minimally invasive procedures like laparoscopic or robotic gastrectomy. The focus is on a type of surgery called D2 lymphadenectomy, which involves removing lymph nodes to help improve the chances of survival. The researchers are testing a scoring system, known as the PhotoNodes Score, which uses high-quality photos taken during the surgery to assess whether any lymph nodes were left behind. This could provide better insight into how well the surgery was performed and its potential impact on patient outcomes.
To participate in this study, patients should be between the ages of 65 and 74 and are undergoing surgery with the intent to cure gastric adenocarcinoma. They can be treated either with chemotherapy before surgery or have surgery as the first treatment. However, patients under 18 years old, those with certain types of advanced cancer, or those undergoing different surgical procedures won't be eligible. Participants in this trial can expect to have their surgery evaluated using these new photographs, which could help improve future treatment for gastric cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients undergoing minimally invasive curative-intent surgery for gastric adenocarcinoma with D2 lymphadenectomy
- • Patients undergoing upfront surgery or treated with a neoadjuvant/perioperative chemotherapy
- • Total or Subtotal Gastrectomy
- • Laparoscopic or Robotic approach
- Exclusion Criteria:
- • Age less than 18 year old
- • Esophago-gastric junction cancer Siewert type I, II or III
- • Metastatic disease
- • Lymphadenectomy less than D2
- • Open surgery
- • Conversion to open surgery
- • Palliative gastrectomy
- • R1 or R2 resection
- • Multivisceral resection except for cholecystectomy
- • Surgical procedures other than subtotal or total gastrectomy
- • A single node station rated as unevaluable by more than one reviewer
About Azienda Ospedaliero Universitaria Di Parma
Azienda Ospedaliero-Universitaria di Parma is a leading hospital and university institution in Italy, dedicated to advancing medical research and patient care through innovative clinical trials. With a strong emphasis on collaboration between healthcare professionals and academic researchers, the organization aims to enhance therapeutic interventions and improve health outcomes across various medical fields. Its commitment to excellence in clinical research is reflected in its state-of-the-art facilities, multidisciplinary approach, and adherence to rigorous ethical standards, positioning it as a pivotal contributor to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parma, , Italy
Milano, Mi, Italy
Cremona, Cr, Italy
Firenze, Fi, Italy
Milano, Mi, Italy
Milano, Mi, Italy
Abano Terme, Pd, Italy
Verona, Vr, Italy
Patients applied
Trial Officials
Giorgio Dalmonte, MD, PhD
Study Chair
Azienda Ospedaliero-Universitaria di Parma
Federico Marchesi, Prof.
Principal Investigator
Azienda Ospedaliero-Universitaria di Parma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported